Latest News

CTA Treatment Regimen Chart for Head and Neck Cancer Updated

CTA Treatment Regimen Chart for Head and Neck Cancer Updated

CTA has updated its treatment regimen chart for the treatment of head and neck cancer to reflect changes put forth by Version 1.2016 of the NCCN Guidelines for Bone Cancer.

Pacritinib Improves Spleen Volume Recovery in Advanced Myelofibrosis

Pacritinib Improves Spleen Volume Recovery in Advanced Myelofibrosis

Pacritinib, an investigational oral multikinase inhibitor, improves spleen volume reduction among high-risk patients with advanced myelofibrosis.

Alternative Metrics of Response Correlate With OS in FIRE-3 Trial

Alternative Metrics of Response Correlate With OS in FIRE-3 Trial

Alternative metrics of response correlated with the overall survival benefit among patients with RAS wild-type metastatic colorectal cancer (mCRC).

Sentinel Lymph Node Biopsy Recommended for Patients With Sarcoma

Sentinel Lymph Node Biopsy Recommended for Patients With Sarcoma

SLNB are more reliable PET-CT for assessing lymph node metastases among young patients with sarcoma.

HSD3B1 Allele Inheritance Linked With ADT Resistance

HSD3B1 Allele Inheritance Linked With ADT Resistance

The HSD3B1 (1245C) allele is linked to androgen deprivation therapy (ADT) resistance among patients with prostate cancer.

MAPIE Failed to Improve Responses in High-grade Osteosarcoma

MAPIE Failed to Improve Responses in High-grade Osteosarcoma

Addition of ifosfamide and etoposide to adjuvant cisplatin, doxorubicin, and high-dose methotrexate (MAP) did not improve event-free survival.

Continuing Docetaxel Therapy May Improve Survival in Prostate Cancer

Continuing Docetaxel Therapy May Improve Survival in Prostate Cancer

For patients with metastatic castration-resistant prostate cancer (mCRPC), 8 cycles of docetaxel may improve superior overall survival.

Compliance With NCCN Guidelines Benefits Patients With Rectal Cancer

Compliance With NCCN Guidelines Benefits Patients With Rectal Cancer

Adjuvant chemotherapy is beneficial for patients with locally-advanced, postoperative rectal cancer.

Financial Conflicts of Interest Prevalent Among NCCN Guideline Authors

Financial Conflicts of Interest Prevalent Among NCCN Guideline Authors

Financial conflicts of interest involving general and industry research payments may be prevalent among authors of clinical practice guidelines.

FDA Grants Priority Review for Rucaparib as Treatment for Advanced Ovarian Cancer

FDA Grants Priority Review for Rucaparib as Treatment for Advanced Ovarian Cancer

The FDA accepted a New Drug Application for accelerated approval of rucaparib.

Adding Daratumumab to Bortezomib, Dex Prolongs PFS in Multiple Myeloma

Adding Daratumumab to Bortezomib, Dex Prolongs PFS in Multiple Myeloma

Adding daratumumab to bortezomib and dexamethasone prolonged progression-free survival in relapsed or relapsed and refractory multiple myeloma.

Degree of Nodal Involvement has Prognostic Significance for NSCLC

Degree of Nodal Involvement has Prognostic Significance for NSCLC

Lymph node staging has prognostic significance for patients with non-small-cell lung cancer (NSCLC) that has metastasized to the chest (M1a).

70-gene Signature May Inform Treatment Decisions for Breast Cancer

70-gene Signature May Inform Treatment Decisions for Breast Cancer

For women with early-stage breast cancer who were determined to be at high clinical risk, not receiving chemotherapy led to a lower rate of survival.

Selumetinib Fails to Meet PFS End Point in KRAS-mutant NSCLC

Selumetinib Fails to Meet PFS End Point in KRAS-mutant NSCLC

SELECT-1 trial of selumetinib as treatment for patients with non-small cell lung cancer (NSCLC) did not meet its end point of progression-free survival.

Trial of Brentuximab Vedotin in CD30+ CTCL Meets Primary End Point

Trial of Brentuximab Vedotin in CD30+ CTCL Meets Primary End Point

The phase 3 ALCANZA study evaluating brentuximab vedotin (Adcetris) met its primary endpoint.

Positive Optimization of Patient Expectations Before Treatment Recommended

Positive Optimization of Patient Expectations Before Treatment Recommended

A patient's expectations may influence his or her adherence to medication regimens, quality of life, and reported side effects.

Risk Factors of Depression Among Patients With Lung Cancer Identified

Risk Factors of Depression Among Patients With Lung Cancer Identified

Risk factors for depression symptoms signify the need for enhanced surveillance among some subgroups of patients with lung cancer.

Pfizer Will Acquire Developer of Enzalutamide

Pfizer Will Acquire Developer of Enzalutamide

Pfizer Inc. will acquire Medivation, a biopharmaceutical company whose portfolio includes enzalutamide (Xtandi), talazoparib, and pidilizumab.

CLL-IPI Validated and Compared With MDACC Index in Newly Diagnosed Patients

CLL-IPI Validated and Compared With MDACC Index in Newly Diagnosed Patients

The chronic lymphocytic leukemia international prognostic index (CLL-IPI) was recently developed using data from approximately 3500 patients.

Baseline Metabolic Tumor Volume Predicts Prognosis of Follicular Lymphoma

Baseline Metabolic Tumor Volume Predicts Prognosis of Follicular Lymphoma

Total metabolic tumor volume is effective for determining the prognosis of high-tumor-burden follicular lymphoma.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters